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ABSTRACT
Iontophoresis is one of the most widely studied active technique for enhancing
transdermal delivery of drugs. However, its ability to enhance the delivery of highly lipophilic
compounds is poor due to lack of any charge and poor water solubility of molecules. Propofol, a
sedative and anesthetic drug was chosen as a one of the model lipophilic drug in this study.
Initially, feasibility of delivery of propofol phosphate, a water soluble prodrug of propofol, via
transdermal route using iontophoresis in combination with chemical permeation enhancers was
investigated. Cathodal iontophoresis in combination with 0.1% sodium dodecyl sulphate
synergistically enhanced the flux of propofol phosphate. The Pharmacokinetic studies were
performed in rat model and the results suggest the plausibility of achieving therapeutically
relevant levels of propofol when delivered via transdermal

route. However, the

pharmacodynamics studies revealed that propofol phosphate would be required at ~10X the dose
of propofol likely due to hydrophilicity and poor distribution into the brain. Therefore, it is
crucial to discover approaches that would enhance the transdermal delivery of propofol in its
parent form. The objective of using iontophoresis is to eventually utilize the feasibility of the
technology to develop a programmable transdermal drug delivery system. Thus, transdermal
delivery of propofol was studied by complexing with sulfobutyl ether-β-cyclodextrin (Captisol®
CAP), a β-cyclodextrin derivative carrying ionizable groups to render propofol amenable to
iontophoresis. The passive permeation flux of propofol was enhanced by four fold due to
ii

complexation with CAP. Application of iontophoresis (0.5 mA/cm2) to CAP-propofol solution
enhanced the transport of propofol by an additional four fold. Pharmacokinetic studies showed a
significant enhancement in the bioavailability of propofol when delivery in the form of complex
by iontophoresis. Further, in vitro transport studies carried out using ibuprofen and testosterone
demonstrated the potential of CAP as transport enhancer for lipophilic drugs. From the
mechanistic studies, the enhancement in the transport of lipophilic drugs after complexation was
found to be due to multiple mechanisms such as transport of intact complex, enhanced
thermodynamic activity of drug at the interface and prolonged recovery of barrier disrupted due
to iontophoresis.
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CHAPTER 1
INTRODUCTION
The skin is the body’s largest organ, accounting for more than 10% of body mass. The
skin consists of four layers; the stratum corneum (non-viable epidermis (SC)), the remaining
layers of epidermis, dermis and subcutaneous tissues. The outer most layer of the epidermis is
SC, which is also known as horny layer or keratin layer. Cross section of SC consisting of 15-25
flattened stacked, hexagonal and cornified cells. Each cell is about 40 μm in diameter and 0.5 μm
in thickness and composed of insoluble keratins and lipids, accounting for about 5% of the SC
weight. The dead cells in the SC protect the deeper tissue, and thus for the majority of the
chemicals tested, diffusion through SC is often the rate limiting step1, 2. The viable epidermis is
typically around 200 μm in thickness and it contains living cells such as keratinocytes,
melanocytes, langerhans cells and merkel cells. Its main functions include synthesis of melanin
for skin pigmentation, sensory perception and immune response.
Dermis is five to seven times thicker than the epidermis (1 – 1.5 mm) and lies below the
epidermis. It is a tough layer of horizontally arranged collagen and elastic fibers with
fibroblasts3. the dermis has numerous structures embedded within it; blood and lymphatic
vessels, nerve endings, pilosebaceous units (hair follicles and sebaceous glands) and sweat
glands (eccrine and epocrine). This layer offers a minimal barrier to the delivery of polar to
moderately lipophilic drugs.
Transdermal delivery of therapeutic agents provide several advantages which includes
avoidance of first pass metabolism, easy termination of dose by removal of patch, easy
1

application for extended period of time by controlling the drug release and many more. The skin
is poorly permeable to drugs, which are hydrophilic (log P < 1). Thus, to enhance the delivery of
hydrophilic

drugs,

chemical

permeation

enhancers

(CPEs)

are

being

utilized

in

dermal/transdermal products. CPEs are chemical substances which facilitate transport of coadministered substances across the skin, mainly by reversibly disrupting the highly ordered
structure of stratum corneum lipids4.
It is well known that the drugs with log P 1-3 (moderately lipophilic) and molecular
weight of < 500 Da are well permeable across the skin5. The rate of permeation of moderately
lipophilic drugs is mainly controlled by the permeability of the skin. Not many approaches are
known to enhance the rate of delivery of moderate lipophilic drugs till date, when there is
requirement of a higher dose or a higher input rate due to rapid clearance of the drug from the
body. Likewise, the extremely lipophilic drugs (log P≥3) would generally penetrate the lipid
domains in the stratum corneum; yet fail the transit further due to highly hydrophilic
environment of the viable epidermis and dermal tissues. The use of chemical enhancers (that are
used to enhance the delivery of hydrophilic drugs) most of which perturb the lipid organization
would rather hamper the delivery of lipophilic drugs. Therefore, the main objective of the present
work was to explore the approaches to enhance the delivery of lipophilic drugs.
Iontophoresis is one of the widely studied active techniques that involve passing
electrical current across the skin in the presence of conductive vehicle. As a result, ions migrate
through the skin towards the electrode of opposite charge. The amount of drug delivered is
directly proportional to amount of current applied, duration of current application and area of the
skin surface in contact with active electrode. Unlike all other techniques, iontophoretic delivery
being programmable, the rate of delivery of drugs could be regulated by adjusting the applied
2

electrical dose (time x current density)6. However, iontophoresis is not suitable for nonpolar
drugs as they lack any charge and possess poor water solubility. The second main objective of
this project was to investigate the potential approaches to render the lipophilic drugs amenable to
iontophoretic delivery across the skin.
Three test lipophilic therapeutic molecules were selected for the research that includes propofol
(log P 4.12), ibuprofen (log P 3.5) and testosterone (log P 2.99).
Transdermal Delivery of Propofol
Propofol (2, 6-diisopropylphenol) is a centrally acting anesthetic usually administered
through intravenous route. Induction of anesthesia with propofol is rapid, and maintenance of
anesthesia can be achieved by either continuous infusion or intermittent bolus injections7. Due to
its clinical safety and efficacy, use of propofol has become drug of choice for procedural
sedation and is used alone or in combination with regional anesthetic agents, especially in case of
pediatric population8-9. The American College of Emergency Physicians (ACEP) defines
procedural sedation as "a technique of administering sedatives or dissociative agents with or
without analgesics to induce a state that allows the patient to tolerate unpleasant procedures
while maintaining cardiorespiratory function”.
Propofol is a clear to slightly yellow oily liquid at room temperature and is highly
lipophilic with a log P of 4.1510. Due to its poor water solubility, propofol is available as an
injectable emulsion containing 1 or 2% of propofol11; hence has been reported to cause moderate
to severe pain at the site of injection12-14. Since propofol emulsion is generally prepared with
lipidic substances such as soybean oil and egg yolk lecithin, the patient suffers from side effects
associated with high lipid intake15. The same is also responsible for other side effects that include
serious allergic reactions, bradycardia, apnea and hypotension16, 17. Since propofol is viscous and
3

water immiscible, pulmonary delivery is not possible18. Oral route is not preferred for propofol
administration either, as the hepatic extraction ratio of propofol was reported to be ~80-90%19.
Therefore, there is need for development of alternate modes of administration of propofol. In this
project, the skin as a route of administration of propofol was investigated. The first approach
involved conversion of propofol to a relatively lesser lipophilic salt form propofol phosphate and
the second approach was to complex with a poly-anionic cyclodextrin. Iontophoresis technology
was used to achieve higher rates transdermal delivery of propofol.

4

CHAPTER 2
TRANSDERMAL IONTOPHORETIC DELIVERY OF PROPOFOL IN THE FORM OF
PHOSPHATE SALT
1. Objective
Iontophoresis is a non-invasive active technique that involves driving of drug ions by the
way of application of mild electric current20. Delivery of propofol by iontophoresis would not be
possible due to its water insolubility and non-polar nature. Therefore, a di-basic phosphate
monoester (prodrug) form of propofol was synthesized and used in this project in order to
improve its water solubility as well as to impart a charge on the molecule. Moreover, phosphate
monoester is one of the most acceptable forms of active pharmaceutical ingredients, as it does
not potentiate toxicity of the parent drug21.
2. Materials
Propofol, butyllithium (2.5 M in hexanes), propylene glycol, sodium dodecyl sulphate,
di-methyl sulfoxide and phosphorus oxychloride were purchased from Sigma Aldrich (St. Louis,
MO), anhydrous ether was purchased from Fisher Scientific (Pittsburgh, PA), Ag/AgCl wire was
purchased from Alfa Aesar (Ward Hill, MA) and hydroxylpropyl methylcellulose (grade E4M)
gift sample was provided by The Dow Chemical Corporation (Midland, MI). All reagents used
were of analytical grade and highly purified deionized water (resistivity ≥ 18.2 MΩ.cm, Barnsted
Nanopure DiamondTM, Barrington, IL) was used for the preparation of all solutions.
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3. Methods
3.1.

Synthesis of Propofol Phosphate (PP)

PP was synthesized by following two steps. In step 1, 2.24 mL of 2.5 M solution in
hexanes of butyllithium (5.6 mM) was added drop wise to 1.0 g of propofol (5.6 mM) in 10 mL
of anhydrous ether under inert atmosphere at -30 ˚C. The solution was stirred for 30min and then
allowed to warm to room temperature. In step 2, the solution from step 1 was added drop wise to
a solution of 0.918 g of phosphorus oxychloride (6.0mM) in 10 mL of ether at -30 ˚C under inert
atmosphere. The solution was allowed to stir until the mixture comes to room temperature. Then
5mL of water was added to the reaction mixture and allowed it to stir for 1 h. 35 mL of sodium
hydroxide (1M) and 30 mL of n-hexane was then added and the aqueous phase was washed with
n-hexane to remove unreacted propofol. Aqueous phase was evaporated to dryness and the solid
residue obtained was extracted with ethyl acetate to get propofol phosphate (Yield was found to
be ~69%).
3.2.

NMR and Mass Spectrum Studies

Chemical structure of the PP salt was characterized by high resolution nuclear magnetic
resonance spectra (1H NMR and 13C NMR). Spectra’s were recorded on a Brucker Ultraspec 400
MHz/100 MHz spectrometer. Chemical shifts were reported in parts per million (δ) and 1H NMR
signals were quoted as s (singlet), d (doublet), t (triplet) and m (multiplet). Electro spray
ionization mass spectrum was recorded on waters micromass (ZQ MM1-LAA 1780).
3.3.

In vitro studies

3.3.1. Passive permeation setup
In vitro skin permeation studies were performed using Franz diffusion apparatus (FDA)
and freshly excised hairless rat abdominal skin. The skin was sandwiched between the donor and
6

receiver compartment with the stratum corneum facing the donor side. The temperature was
maintained at 37 ± 1◦C by using a water circulator. The donor compartment was filled with 0.5
mL of drug solution/ formulation and the receiver compartment with 5 mL of saline. The active
diffusion area was 0.64 cm2. The electrodes were made out of Ag/AgCl. The electrical resistance
of the rat skin was measured using digital multi meter and waveform generator (Agilent
Technologies, Santa Clara, California). Skin with resistance 20 kΩcm2 and greater was used for
the permeation study. The samples from the receiver compartment were collected at
predetermined time points to estimate the amount of propofol/PP permeated across the skin,
using high-performance liquid chromatographic technique (HPLC). All the points in the graphs
representing in vitro studies are average of six trials ± SD.
3.3.2. Concentration dependent in vitro permeation of PP
In vitro permeation studies were carried out with four different concentrations of PP (1, 5,
30 and 100 mg/mL) in the donor to investigate the effect of concentration on the passive
transdermal flux.
3.3.3. Effect of Chemical Permeation Enhancer on the permeation of PP
The effect of chemical permeation enhancers (CPE) like propylene glycol (PG), sodium
dodecyl sulphate (SDS) and dimethyl sulfoxide (DMSO) at 30%, 0.1% and 30% concentration
levels respectively, on the passive transdermal flux of PP was assessed. The enhancer, with
relatively higher enhancement efficiency was chosen for further studies.
3.3.4. Iontophoretic delivery of PP
A similar Franz diffusion cell setup described in the previous section was used in this
study. Constant current cathodal iontophoresis was performed using Phoresor iontophoresis unit
(Iomed, Salt Lake City, Utah) at a current density of 0.5 mA/cm2. The donor compartment was
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filled with 30 mg/mL of PP and the receiver compartment with 5 mL of saline. One milliliter of
samples was collected from the receiver compartment at predetermined time points and analyzed
for PP using HPLC.
3.3.5. Effect of combination of chemical permeation enhancer with iontophoresis
The effect of sodium dodecyl sulfate (SDS) on iontophoretic flux was evaluated by
incorporating SDS in the donor compartment along with PP, at concentration level of 0.1% W/V.
3.3.6. Iontophoretic delivery of PP from gel formulation
Semi-solid gel formulation was prepared using hydroxypropyl methylcellulose (HPMC)
using hot/cold technique22. Briefly, one-third of the total volume of water was heated to 90◦C and
the HPMC (4% w/ v) was incorporated with continuous stirring until a uniform dispersion was
obtained. PP was dissolved in remaining amount of water and then added to the HPMC
dispersion, under continuous stirring. The solution was cooled to 30◦C to form a semi-solid gel
while continuously stirring for homogeneity. In vitro drug transport studies were performed, by
placing 1 g of gel formulation in the donor compartment. The other experimental conditions
were maintained same as discussed under the section Iontophoretic Delivery of PP
3.4.

Pharmacokinetic studies

Pharmacokinetic studies were carried out in Sprague–Dawley rats. The Institutional
Animal Care and Use Committee (IACUC) at the University of Mississippi (IACUC #11-008)
approved the studies. The rats were divided into two groups (n = 6) with one group serving as
control (passive) and the other as iontophoresis group. The animals were anesthetized using
ketamine (80 mg/mg) and xylazine (10 mg/kg) via intraperitoneal route during the period of
study.
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Custom-designed reservoir type patch of 10cm2 area were used for pharmacokinetic
studies. The patch was designed by loading 2 g of HPMC gel formulation containing 30 mg/mL
PP and 0.1% SDS, on the polyolefin backing membrane. The patches were placed on the dorsal
skin surface of the rat. Alongside, another patch containing conducting gel (Sigma gel; Parker
Laboratories, Inc., Fairfield, New Jersey) was also placed 2 cm apart on the dorsal surface of the
rat. To perform iontophoresis, cathodal electrode was connected to the patch containing propofol
gel formulation, and the anodal electrode was connected to the patch containing conducting gel.
Iontophoresis was performed by applying constant current of 0.5 mA/cm 2 across the electrodes
by using Iomed Phoresor II dose controller (Iomed Inc.) for a period of 4 h. In case of control,
the set up was similar except that the current was not applied. Blood samples were collected into
dry heparinized tubes from the retro orbital plexus for 6 h, at predetermined time points.
Propofol was then extracted and estimated from the blood samples using a validated HPLC
method as described under section Analytical Methods.
3.5.

Method for Extraction of Propofol from Plasma

Samples Plasma was separated from the blood samples by centrifugation. One milliliter
of acetonitrile was added to 100 μL of plasma and vortexed. The mixture was centrifuged at
15,000g for 10 min at 4◦C. The clear supernatant was then separated and the propofol content
was measured using HPLC
3.6.

Analytical Methods

The HPLC system (Waters Corp, Milford, MA) consisting of model 1525 isocratic
chromatographic pump equipped with an autosampler (Waters 717 plus), a UV detector (Waters
2487) and a reversed phase symmetry® C18 (4.6 x 150 mm; 5 µm particles) column with a
security guard cartridge, was used. Analyses of PP samples were carried out at a wavelength of
9

214 nm, and the mobile phase consisted of a mixture of water, acetonitrile and tri-fluroacetic
acid (55:45:1 v/v) with an optimized flow rate of 1mL/min.
Propofol extracted from plasma samples was analyzed at 270 nm with mobile phase
consisting of water and methanol (20:80 v/v)23. Calibration curves were prepared using methanol
as solvent and the linearity was (R2 > 0.99) over the concentration range 10 to 10,000 ng.
4. Results and Discussion
Propofol phosphate di-sodium salt (a white crystalline solid) was synthesized and its
structure was characterized by 1H NMR and 13C NMR. Electron spray ionization mass spectrum
study confirmed the mass of PP (303.2 Da). Chemical structure of propofol and propofol
phosphate was shown in figure 1. Results obtained from the NMR and mass spectrum were
consistent with the structure. 1H NMR and
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C NMR chemical shift values of propofol and

propofol phosphate was given in the Table 1 and Table 2, respectively.

Figure 1: Structure of Propofol and Propofol Phosphate
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S.No

Protons

Chemical Shift
Propofol (CDCl3)

PP (D2O)

1

Isopropyl CH3’s

1.43(d)

1.10(d)

2

Isopropyl CH’s

3.31(m)

3.44(m)

3

-OH

4.96(s)

-

4

Ar-C4-H

7.07(t)

5

Ar-C3-H & C5-H

7.23(d)

7.14(m)

Table 1: 1H NMR chemical shifts of propofol and propofol phosphate. Singlet (s), Doublet
(d), Triplet (t) and Multiplet (m)

S.No

Carbons

Chemical Shift
Propofol (CDCl3)

PP (D2O)

1

Isopropyl terminal ‘C’ s

22.7

22.7

2

Isopropyl middle ‘C’ s

27.1

26.6

3

Ar-C3 & C5

120.6

123.9 & 123.9

11

4

Ar-C4

133.6

125.0

5

Ar-C2 & C6

123.4

141.6 & 141.7

6

Ar-C1

149.9

147.0

Table 2: 13C NMR chemical shifts of propofol and propofol phosphate

4.1.

Spectral Data

Propofol: 1H NMR (400 MHz, Chloroform-d) δ 7.23 (d, J = 7.6 Hz, 2H), 7.07 (t, J = 7.6 Hz,
1H), 4.96 (s, OH), 3.31 (h, J = 6.9 Hz, 2H), 1.43 (d, J = 6.9 Hz, 12H). 13C NMR (101 MHz,
cdcl3) δ 149.87, 133.62, 123.36, 120.61, 27.07, 22.70. ESI-MS: 179 (M+1).
Propofol Phosphate: 1H NMR (400 MHz, D2O) δ 7.17–7.07 (m, 3H), 3.44 (p, J = 6.9 Hz, 2H),
1.10 (d, J = 6.9 Hz, 12H).
13C NMR (101 MHz, D2O) δ 147.00, 141.66, 141.63, 125.01, 123.96, 123.94, 26.57, 22.72.
ESI-MS: 303 (M+1).
4.2.

Concentration dependent in vitro permeation of PP

In vitro passive permeation studies were performed at four different concentrations (1, 5,
30 and 100 mg/mL) to assess the effect of concentration on the steady state transdermal flux of
PP. From the results it was found that, an increase in PP concentration from 1-30 mg/mL
increased the steady state flux from 1.90±0.21 µg/cm2/h to 8.52±0.82 µg/cm2/h respectively.
However, further increase in concentration to 100 mg/mL, did not lead to significant
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proportionate increase in the flux (9.83±1.12 µg/cm2/h) (Fig 2). Therefore, further studies were
performed at donor concentration of 30 mg/mL of PP.

Figure 2: The effect of concentration of propofol phosphate in the donor on its
transdermal flux
4.3.

Effect of chemical permeation enhancers on the passive permeation of PP

Chemical permeation enhancers are known to enhance the permeation of therapeutic
agents across the skin. Predominantly, the mechanism of enhancement has been due to the
interaction with the stratum corneum (skin lipids or proteins or both) and/or owing to the
increase in the thermodynamic activity of drugs24. In this study, some of the well-known skin
permeability enhancers such as PG, SDS, and DMSO were used as CPEs at 30% v/v, 0.1% w/v,
and 30% v/v concentration levels, respectively. PG is known to increase the solubility of drugs in
the skin lipids and thereby enhance the permeability of therapeutic agents. Yamato et al 25 studied
the effect of different CPEs on transdermal permeation of propofol. The authors reported a
fourfold enhancement in the in vitro permeation flux of propofol across the rat abdominal skin
when 30% PG was used as CPE. However, in the present study PG (at the same concentration)
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decreased the in vitro passive permeation flux of PP [6.23 ± 1.03 μg/cm2/h with PG vs. 8.52 ±
0.82 μg/cm2/h in case of control].
Dimethyl sulfoxide was the other enhancer screened in the present study, as it is one of
the widely used transdermal permeation enhancer. Several studies have demonstrated that
DMSO is effective in promoting the permeation of larger number of hydrophilic and lipophilic
molecules.26,27 The enhancer effect is reported to be concentration dependent and at
concentration above 60%, it has been reported to extract skin lipids apart from altering the
protein structure and thereby enhances the permeation of drug molecules.24 However, at this high
concentration, DMSO has been shown to cause erythema and burning sensation.28 Zafar et al.29
have studied the effect of various penetration enhancers along with DMSO to deliver labetalol
hydrochloride via transdermal route. From the in vitro permeation studies, they concluded that,
upon increasing the concentration of DMSO, the enhancement factor was found to increase and
showed maximum enhancement (1.165) at 10% v/v.29 Therefore, in the present study, DMSO
was studied as permeation enhancer at 30% concentration. However, the passive transdermal
flux of PP was not enhanced even in presence of DMSO [8.12 ± 2.08 μg/cm2/h].
Treating epidermis with surfactants has been demonstrated to significantly decrease the
skin barrier functionality, in percutaneous drug absorption.30 SDS, an anionic surfactant, known
to interact with the skin proteins and lipids thereby enhances the percutaneous absorption.31,32
Surfactants are known to cause skin irritation upon exposure to higher concentrations. 33,34 In the
present study, effect of SDS was investigated at 0.1% concentration level, at which it is known to
be safe to use.35 In a skin irritation study performed by Agner and Serup35 on human subjects, the
dose–response relationship on skin irritation was studied and the response was quantified by
measuring transepidermal water loss, blood flow, skin color, and edema in the skin. From the
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irritation studies, authors concluded that the irritation potential increased significantly rapidly
only after 0.25%. The results clearly indicate the clinical safety of SDS use at 0.1%
concentration levels. Wang et al.36 have studied the effect of SDS on permeation of
hydrocortisone; they found that the hydrocortisone flux was increased by approximately fourfold
at 0.1% SDS when compared with control.36 In agreement with these results, the passive
permeation flux of PP in the presence of 0.1% SDS resulted in the flux of 13.43 ± 0.73 μg/cm2/h,
which was significantly higher than passive flux in case of control. Therefore, further studies
were carried with SDS as permeation enhancer at 0.1% concentration level.
Several clinical investigation reports on propofol pharmacokinetics have been published
till date. In general, the target propofol plasma concentration for sedation at level 2 (drowsy), 3
(drowsy, responds to verbal stimulations) and 4 (responsive to physical stimulation only) were
found to be 1-2 µg/ml37. Daisuke and co-workers have assessed the required plasma
concentration of propofol and infusion rate of achieving sedation level 3 in humans. The authors
reported that the target plasma concentration of propofol required for achieving sedation score of
level 3 is 0.85 ± 0.24 µg/mL. With the clearance value of propofol being 1.83 L/min, the
required input rate for achieving the above mentioned plasma concentration was 1.74 mg/kg/h 38.
Based on these reports, the required target rate of input of propofol phosphate (1.7M
concentration of propofol phosphate is equal to 1M of propofol) would be 2.98 mg/kg/h. For the
purpose of this project, if one considers pediatric patient of weight ~2 kg, then the average
transdermal input rate (from the overall patch) to be achieved would be 5.96 mg/h. If the
proposed size of the delivery device is about 10 cm2, then the target flux to be achieved would be
596 µg/h/cm2.
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4.4.

Iontophoretic delivery of PP

The iontophoresis application enhanced the transdermal flux of PP over passive (without
SDS) by ~seven fold. However, there is need to improve the flux further to achieve the target
flux. A number of studies have demonstrated the ability of chemical permeation enhancers to
potentiate the effect of iontophoresis and improve the drug delivery significantly39-41. Rastogi
and co-workers have studied the effect of CPEs on iontophoretic delivery of insulin. Results
from their studies concluded that CPEs in combination with iontophoresis have enhanced the
delivery of insulin by ~45 fold when compared to CPEs and iontophoresis alone42. In the present
work, SDS was found to be one of the promising enhancer from passive drug permeation studies.
Therefore, SDS was incorporated in the donor compartment solution with an objective of
assessing the ability of SDS to enhance the iontophoretic mediated transdermal delivery of PP.
The flux resulted from the in vitro iontophoretic transport studies in the presence of 0.1% SDS
was found to be 306.2±32.82 µg/cm2/h, which was significantly (~fivefold) more when
compared to iontophoresis of PP in the absence of SDS (60.37±8.63 µg/cm2/h) (Fig 3). More
importantly, the iontophoretic flux of drug in presence of SDS was found to be somewhat nearer
to calculated transdermal target flux.
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Figure 3: Iontophoretic mediated delivery of PP across the rat skin, in presence of
0.1% SDS in the donor (■) and without SDS (♦) in the donor
4.5.

In vitro permeation of PP from gel formulation

Hydroxypropyl Methylcellulose (HPMC) is widely used as suspending and stabilizing
agent in various topical formulations, due to its semisynthetic and viscoelastic nature. High water
content in HPMC gel formulation helps in good wetting, high partitioning of drug into the skin
and also acts as a solvent medium for iontophoresis43. HPMC (4% W/V) gel prepared with 0.1%
SDS and 30% PP was used for in vivo iontophoretic studies. Prior to in vivo studies, the
iontophoresis mediated drug transport profile from the gel formulation was assessed across the
rat skin. The steady state iontophoretic flux of PP from the gel was 249.24±6.12 µg/cm2/h, which
was significantly less than that observed from the solution (306.2±32.82 µg/cm2/h) owing to the
retarded ionic mobility due to higher viscosity of the gel (fig 4). At this flux, one would need
approximately 2.4 times (23.9 cm2) the proposed area of application for the drug delivery device
to achieve the target rate of input. Apparently, several transdermal drug delivery patches are of
about this size and seems doing well from the patient acceptance standpoint. For example,
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Estraderm MX® 100 is a marketed patch used to deliver estradiol with patch size of 44 cm 2.
Nitro-Dur®, is another example of marketed transdermal patch, which is used to deliver
nitroglycerin with patch size of 40 cm2 and others include, Nicorette® is marketed to deliver
nicotine with patch size of 30 cm2. Therefore, in the present study the required patch size (~24
cm2) to achieve the target flux should be ideal and acceptable.

Figure 4: In vitro permeation of PP from gel formulation (♦) and solution (■)
4.6.

Pharmacokinetic Studies

The Pharmacokinetic studies were performed in rat model to assess the feasibility of
transdermal delivery of PP, in vivo. Following the transdermal delivery, PP is known to convert
to propofol and inorganic phosphate, immediately upon entry into systemic circulation. The time
course of propofol concentration in plasma is shown in Fig 5. The amount of propofol present in
plasma samples in control group (Passive) was below the detectable levels at all the time points
during the study. Whereas, in case of iontophoresis group; initially, the plasma propofol
concentration increased with time. However, there was no significant difference in the
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concentration between 3rd and 4th hour indicating an inclination towards steady state
concentration. Apparently, the drug has not formed a significant reservoir, as the plasma
propofol concentration dropped significantly, immediately after the removal of the patch after
fourth hour.

Figure 5: Plasma concentration of propofol after transdermal delivery of PP at 30 mg/mL
and 0.1% SDS with iontophoresis (♦) and without iontophoresis (■).
The plasma concentration-time profile was fit to a non-compartmental model and the
pharmacokinetic parameters were calculated. The elimination half-life of the drug was found to
be 37.20 ± 6.82 min, which is in agreement with elimination half-life 24±12 min reported in the
literature2. The results of this study demonstrate iontophoresis ability to deliver propofol via
transdermal route.
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5. Conclusions
Combination of iontophoresis and chemical permeation enhancer, SDS was found to
enhance the transdermal delivery of PP synergistically. These studies suggest that propofol could
be delivered transdermally via iontophoresis in the form of its phosphate salt.
However, the pharmacodynamics studies (unpublished data) revealed that propofol phosphate
would be required at ~10X the dose of propofol likely due to hydrophilicity and poor distribution
into the brain. Therefore, it is crucial to discover approaches that would enhance the transdermal
delivery of propofol in its parent form. The objective of using iontophoresis is to eventually
utilize the feasibility of the technology to develop a programmable transdermal drug delivery
system.
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CHAPTER 3
TRANSDERMAL IONTOPHORETIC DELIVERY OF PROPOFOL BY COMPLEXING
WITH ANIONIC CYCLODEXTRIN
Graphical Abstract

Propofol

Sulfobutyl ether-β-cyclodextrin
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P-CAP Complex

1. Introduction
Cyclodextrins (CDs) are commonly used as pharmaceutical excipients, mainly to solubilize
the water insoluble drugs. CDs are cyclic oligosaccharides with a hydrophobic central cavity and
hydrophilic outer surface. Their molecular structure attributes them some unique properties. The
hydrophilic exterior of the CD makes them water soluble, but the hydrophobic cavity provides a
microenvironment of appropriate size lipophilic molecules. In aqueous solutions, CDs are
capable of forming inclusion complexes with many therapeutic agents by taking up a whole
molecule or rather some non-polar part of the molecule into the hydrophobic cavity. The noncovalent complex offers several advantages including the possibility of enhanced water solubility
and solution stability44, 45.
The objective of this project was to investigate, if cyclodextrin derivatives carrying ionizable
groups could be utilized to complex with non-polar lipophilic drug, propofol to render it
amenable to transdermal delivery by iontophoresis. Sulphobutyl ether-β-cyclodextrin (Captisol®
(CAP)), a derivative of β-cyclodextrin with an average molecular weight of 2164 Da and seven
negative charges due to ionizable sulfate group on its surface was chosen as complexing agent.
2. Materials
Sulphobutyl ether-β-cyclodextrin (Captisol®) was obtained as gift sample from Ligand
Pharmaceuticals, La Jolla, CA) and Rhodamine labeled CAP (R-CAP) was obtained from
CycloLab Ltd, Budapest, Hungary. Propofol, deuterium oxide, deuterated chloroform, menthol,
ethanol, oleic acid and propylene glycol was purchased from Sigma Aldrich Corporation, St
Louis, MO. Ag wire was from Alfa Aesar, Ward Hill, MA. Isopropyl myristate and Dialysis
membrane molecular weight cut off (MWCO) 1000Da was from Spectrum Chemicals, New
Brunswick, NJ. All other chemicals used were of research grade.
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3. Methods
3.1.

Phase Solubility Studies

Phase solubility studies were performed according to the standard protocol46. Solubility
measurements were carried out at constant temperature (25 ˚C) using different concentrations of
aqueous solutions of CAP. A large excess of propofol (200 mg) was added to 3ml of water with
accurately weighed amount of CAP and diluted to concentrations of 0.02, 0.04, 0.08, 0.1 and
0.15 M in screw capped scintillation vials. The resulted solution was vortexed for 5 min and was
shaken for 5 days using rotary LabquakeTM tube shaker (Labindustries, Inc. Berkeley, CA).
Then, an aliquot of aqueous phase from each mixture was withdrawn, centrifuged for 15 min at
13000 RPM and the supernatant was discarded and the remaining content was filtered through
0.45 µm cellulose acetate membrane filter47. A portion of clear filtrate was diluted appropriately
and analyzed using high performance liquid chromatography (HPLC).
3.2.

Preparation of propofol-captisol® complex

Propofol:captisol® (P-CAP) inclusion complex was prepared by freeze-drying method. The
aqueous solution of P-CAP complex was prepared by dissolving propofol (100 mg) in 10 ml of
18% w/v solution of CAP in distilled water. The resulting mixture was vortexed for 15 min and
sonicated for 20 min followed by setting aside at 25 ˚C for 48 h to attain equilibrium solubility.
The clear solution was then subjected to freeze drying for 24 h to obtain white powder.
3.3.

UV-Spectrophotometric Studies

Samples were prepared by dissolving freeze-dried complex and neat propofol (control) in
distilled water. The samples were analyzed using UV spectrophotometer and any shift in the λ max
or absorption intensity was recorded.
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3.4.

NMR spectroscopy

Inclusion complex of P-CAP was characterized by high-resolution nuclear magnetic
resonance spectra (1H NMR). Samples of propofol and P-CAP complex were prepared by
dissolving, a portion of freeze-dried powder in deuterium oxide (D2O) and propofol in deuterated
chloroform (CDCl3). Spectra’s were recorded on a Brucker Ultraspec 400 MHz/100 MHz
spectrometer (Brucker Biospin Corporation, Woodlands, TX). Chemical shifts were reported in
parts per million (δ) and 1H NMR signals were quoted as s (singlet), d (doublet), t (triplet), and m
(multiplet).
3.5.

In vitro transport studies

3.5.1. Preparation of Porcine Epidermis
Freshly excised porcine belly skin was obtained from the local abattoir. The obtained skin
was washed carefully with saline followed by removal of subcutaneous fat and the pieces of the
skin were wrapped in aluminum foil and heated to 60 °C for 2 min. Then the epidermis was
gently peeled off the skin and stored at 4 °C until further use.
3.5.2. General Experimental Setup
A vertical Franz diffusion apparatus (Logan Instruments, Somerset, NJ) was used for all
transport studies. The receiver compartment was filled with 5 mL of freshly prepared phosphate
buffered saline (PBS) (pH 7.4) with 30% alcohol and donor compartment with 0.5 mL of
permeant solution. The electrical resistance of epidermis was measured with the help of an
electric circuit consisting of a waveform generator and digital multimeter (Agilent Technologies,
Santa Clara, CA). Epidermis with a resistance ≥20 kΩcm2 was considered for permeation
studies. One mL of sample from the receiver compartment was withdrawn at pre-determined
time points and estimated for propofol using HPLC.
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3.5.3. Transport studies across porcine epidermis
In vitro passive permeation studies were carried out using the experimental setup described
in the above section. P-CAP complex at 10 mg/mL concentration in the donor compartment was
used for transport studies across the porcine epidermis, whereas propofol dissolved in 30%
alcohol was used as control at same concentration. Permeation studies were carried out for a
period of 8h and samples were analyzed for propofol using HPLC technique. The details of
analytical method are discussed in section 3.7.
For in vitro iontophoretic permeation of P-CAP complex, the experimental setup remained
same as described in the above section. Additionally, constant current cathodal iontophoresis was
performed using Phoresor® iontophoresis unit (Iomed, Salt Lake City, UT) at a current density of
0.5 mA/cm2.
3.6.

Pharmacokinetic Studies
Pharmacokinetic studies were carried out in Sprague–Dawley rats. The rats weighing ~250–

300 g were purchased from Harlan Laboratories (Indianapolis, Indiana) and maintaining 12 h
light–dark cycle allowed to acclimate in an animal facility with unlimited access to food and
water. The rats were divided into two groups. One of the groups was passive transdermal
delivery (n = 4) and the second group was iontophoretic delivery of propofol from its CAP
complex (n = 6). In both the groups, the time course of drug in the plasma was determined
following transdermal administration of propofol from its complex. The animals were
anesthetized using ketamine (80 mg/mg) and xylazine (10 mg/kg) via the intraperitoneal route
during the period of study. Custom made patch system loaded with P-CAP complex (10 mg/mL)
was applied to both the passive and iontophoresis groups. The patches were placed on the lateral
surface of the skin. Alongside, another patch containing conducting gel (Sigma gel; Parker
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Laboratories, Inc., Fairfield, New Jersey) was also placed on the rat. To perform iontophoresis, a
cathodal electrode was connected to the patch containing P-CAP complex solution and the
anodal electrode was connected to the patch containing conducting gel. Iontophoresis was
performed by applying a constant current of 0.5 mA/cm2 across the electrodes by using Iomed
Phoresor II dose controller (Iomed Inc.) for a period of 4 h. In the case of control, the setup was
similar except that the current was not applied. Blood samples (200 μl) were withdrawn for a
period of 6 h from the retro-orbital plexus and placed in heparinized tubes and centrifuged at
8000 g for 3 min. The plasma proteins were precipitated with acetonitrile and the supernatant
was analyzed for drug content by using validated HPLC method, which is described in detail
under Section 3.7.
3.7.

Analytical Method

The HPLC system (Waters Corp, Milford, MA) consisting of model 1525 isocratic
chromatographic pump equipped with an auto-sampler (Waters 717 plus), a UV detector (Waters
2487) and a reversed phase Symmetry® C18 (4.6 x 150 mm; 5 µm particles) column with a
security guard cartridge, was used. Analysis of propofol samples were carried out at a
wavelength of 254 nm, and the mobile phase consisted of a mixture of water and methanol
(20:80 v/v) with an optimized flow rate of 1 mL/min. Standard solutions of propofol were
prepared in methanol and calibration curve was plotted against area vs concentration48.
4. Results
4.1.

Phase solubility studies

The phase solubility studies revealed that different concentrations of aqueous solutions of
CAP and propofol in solution were correlated linearly representing an A L type curve4s. This data
suggests that the stoichiometry of the complex is most likely to be 1:1. Since, the slope of this
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plot is less than 1 (0.0074), the apparent stability constant was calculated using the equation Kc =
Slope/S0 (1-slope) (where S0 is the solubility value of propofol in water) and was found to be
1426.8 M-1 (Fig 6).

Figure 6: Phase solubility studies of propofol and CAP.
4.2.

Characterization of inclusion complex

Generally complexation with cyclodextrin leads to a change in the absorption spectrum of
guest molecules due to inclusion of chromophore of the guest molecule in cyclodextrin50. In the
present case, the UV absorption spectra indicated a small shift in the λmax of propofol from 254 to
255.5, indicating complex formation between CAP and propofol.
Further, NMR studies were performed to confirm the complex formation between
propofol and CAP. NMR spectroscopy is one of the most widely used techniques to study CD
inclusion complexes51. 1H NMR spectroscopic studies were carried out to investigate the
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formation of complex between propofol and CAP. It is clear from the data in Table 1 that there is
a significant down field shift with all the protons of propofol in the presence of CAP. Likewise,
the chemical shifts in case of protons corresponding to CAP in the presence and absence of
propofol further confirmed the formation of inclusion complex (Table 2)52.
Propofol

P-CAP complex

Difference in

Chemical Shift

Chemical Shift

the Chemical

Values

Values

Shift Values

H-3

6.5

7.07

0.57

Doublet

H-4

6.4

6.88

0.48

Triplet

H-5

2.5

3.24

0.74

Septet

H-6

0.7

1.2

0.5

Doublet

Peak
Propofol Proton

Multiplicity

Table 3: 1H chemical shifts corresponding to propofol in the absence and presence of CAP.

CAP proton

H-1

CAP

P-CAP Complex

Difference in the

Chemical Shift

Chemical Shift

Chemical Shift

Values

Values

Values

5.13

5.05

0.08
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H-2

1.73

1.72

0.01

H-3

3.60

3.55

0.05

H-4

2.90

2.87

0.03

H-5

3.89

3.77

0.12

Table 4: 1H chemical shifts corresponding to CAP in the absence and presence of propofol.
4.3.

Transport studies across porcine epidermis

4.3.1. Passive transport studies
In vitro passive and iontophoretic transport of propofol from propofol alone and P-CAP
complex was investigated across the porcine epidermis. The passive flux of propofol from PCAP complex was 17.04±2.41 µg/h/cm2, whereas passive flux of propofol from control set (only
neat propofol was placed in the donor) was found to be 4.64±1.68 µg/h/cm2 (Fig 7). Indeed, this
was intriguing data as the passive delivery of propofol was enhanced almost 4 fold by the
complex as compared to neat propofol. This suggests the likelihood of CAP possessing the
property of enhancing passive transdermal delivery of lipophilic drugs. In the past, several
research groups have extensively studied the effect of different CDs as transdermal permeation
enhancers. Recently, Badili and co-workers have reported that CAP enhanced the transport of
calcipotriol across dialysis membrane barrier from an emulgel formulation. The enhancement in
permeation of calcipotriol in presence of CAP was attributed to improved solubility and
dissolution characteristics of the complex over the neat calcipotriol. However, the authors did not
provide any information on permeation studies across biological membrane to demonstrate the
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potential of CAP as transdermal permeation enhancer53. In another study, Vollmer and coworkers have investigated the effect of 20% aqueous solutions of 2-hydroxypropoyl-β-CD
(HPCD) and 2,6 - dimethyl-β-CD (DBCD) on the transdermal permeation of liarozole on rat
model, in vivo. They found a 3-fold enhancement in absorption of drug when applied a solution
of HPCD. Whereas, pretreatment with 20% w/v DBCD for 4h enhanced the permeation of
liarozole by ~9 fold. The mechanism of drug penetration enhancement was investigated using
differential scanning calorimeter (DSC) as a tool. The authors reported that DBCD was found to
disrupt the SC barrier thus enhancing the skin permeability. On the other hand, HPCD was found
to have no interaction with the stratum corneum and rather enhanced the partitioning of the drug
into skin54. There are no reports on the use of CAP as a skin transport-enhancing agent so far.

Figure 7: In vitro transport profile of propofol across porcine epidermis when the donor
solution was placed with, neat propofol (Control) (▲), P-CAP complex (equivalent to 10
mg/ml propofol) (■). Transport of propofol by iontophoresis from P-CAP complex solution
(♦).
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4.3.2. Iontophoretic transport studies
The passive flux of propofol from P-CAP complex was further enhanced by four fold
(62.35±5.27 µg/h/cm2) due to application of cathodal iontophoresis. Cathodal iontophoresis was
applied as the P-CAP complex was expected to possess a net negative charge. This data
supported our hypothesis that complexation with CAP would render the lipophilic molecule
amenable to iontophoresis. There was a significant change in the pH of the donor compartment
during iontophoresis as we used aqueous solution of the complex instead of buffers to keep the
solution devoid of any competing ions. Considering the low pKa value of sulfonic acid groups on
the CAP, increase in the pH in donor compartment due to hydrolysis of water during
iontophoresis is not likely to affect the iontophoretic transport significantly55. Although it is
obvious to speculate that the predominant mechanism contributing to enhance delivery of
propofol (from P-CAP) by iontophoresis would be electrorepulsion, the role of other potential
mechanisms cannot be completely neglected. Mechanistic studies were performed to assess the
potential role of other possible mechanisms in enhancing the transport of propofol across the
epidermis passively as well as iontophoretically form the P-CAP solution, which is discussed in
detail in the next chapter.
4.4.

Pharmacokinetic Study

The plasma propofol level in control group (passive) was below detection at all-time points
during the study. Iontophoresis of propofol alone (without CAP) was not possible due to the
absence of any charge on the propofol molecule. The plasma concentration–time profile after
transdermal iontophoretic delivery in the form of P-CAP was fitted to a non-compartmental
model and the elimination half-life of the propofol was found to be 22.71 ± 5.77 min, which is in
agreement with elimination for intravenous administration reported in the literature56 (Fig 8).
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Figure 8: Plasma concentration of propofol after transdermal delivery of P-CAP from
patch loaded with 10 mg/mL of P-CAP complex with iontophoresis (♦) and without
iontophoresis (passive delivery) (■).
Further, propofol kinetics in the brain following I.V infusion and transdermal
iontophoresis was found to be comparable (Fig 9).
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Figure 9: Pharmacokinetic studies of propofol in brain following I.V infusion (■) and
transdermal iontophoresis (♦) of P-CAP complex.
5. Conclusions
Phase solubility, 1H NMR and UV-spectrophotometric studies confirmed Propofol and CAP
complex formation. The results obtained from the in vitro permeation studies demonstrated the
feasibility of iontophoresis of lipophilic drugs by the way of complexing with anionic
cyclodextrin. Also, the results from pharmacokinetic study clearly demonstrate the ability of
iontophoresis to deliver propofol via transdermal route after complexing with CAP, which could
potentially overcome the disadvantages of marketed lipid formulation.
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CHAPTER 4
TRANSDERMAL IONTOPHORETIC DELIVERY OF IBUPROFEN

1. Introduction
Ibuprofen is an effective non-steroidal anti-inflammatory drug (NSAID) often used in the
treatment of acute and chronic arthritic conditions57. Since, the oral delivery of ibuprofen is
associated with severe gastric side effects; there is need for development of alternate routes of
delivery. Transdermal delivery of ibuprofen from different formulations was studied by several
research groups; however inherent transdermal permeability is low due to higher log P value58, 59.
Therefore, the effect of complexation with anionic cyclodextrin (CAP) in enhancing the
permeation of lipophilic drug, ibuprofen was studied.
2. Materials
Sulphobutyl ether-β-cyclodextrin (Captisol®) was obtained as gift sample from Ligand
Pharmaceuticals, La Jolla, CA). Ibuprofen was purchased from Sigma Aldrich (St. Louis, MO).
Deuteriumoxide (99.5 mol% D) were purchased from Sigma-aldrich (St. Louis, MO, USA). All
other chemicals used were of research grade.Methods

2.1.

Phase solubility studies

Phase solubility studies were performed according to the procedure described in the previous
chapter and the Ibuprofen - sulfobutyl ether-β-cyclodextrin (I-CAP) complex was prepared and
characterized by solubility and NMR studies.
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2.2.

NMR spectroscopy

The 1H-NMR was performed using a Bruker Avance 400 MHz spectrometer for protons in
deuterium oxide as a solvent. The δ scale relative to tetramethylsilane was calibrated to the
solvent value δ = 4.69 ppm for D2O.

2.3.

In vitro Permeation Studies

The passive and iontophoretic permeation of ibuprofen from cyclodextrin complex solution was
carried out using vertical Franz diffusion apparatus. I-CAP complex at 10 mg/mL concentration
in the donor compartment was used for transport studies across the porcine epidermis, whereas
ibuprofen dissolved in 50% alcohol was used as control at same concentration. Permeation
studies were carried out for a period of 24 h and samples were analyzed for ibuprofen using
HPLC technique.

3. Results

3.1.

Phase Solubility Studies

The phase solubility studies revealed that different concentrations of aqueous solutions of CAP
with ibuprofen in solution were correlated linearly representing an AL type curve (Fig 10).
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Figure 10: Phase-solubility profiles of Ibuprofen and CAP.
3.2.

NMR Studies

The formation of the complexes between ibuprofen and CAP was studied using 1H-NMR
spectroscopy. Proton NMR spectra were recorded from the solutions of CAP and I-CAP in D2O
to simulate the complexation in aqueous condition. The chemical shifts in case of protons
corresponding to CAP in the presence and absence of ibuprofen confirmed the formation of
inclusion complex60.
3.3.

Permeation studies across porcine epidermis

Passive delivery of I-CAP solution formulation resulted in flux of 1.98±0.71 µg/cm2/h, which is
comparable with the flux achieved in case of alcoholic solution of ibuprofen used as control
(1.93±0.24 µg/cm2/h) (Fig 11).
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Figure 11: In vitro transport profile of ibuprofen across porcine epidermis when the donor
solution was placed with, ibuprofen in 50% alcohol (Control) (♦), I-CAP complex
(equivalent to 10 mg/ml ibuprofen) (■). Transport of ibuprofen by iontophoresis from ICAP complex solution (▲).

Further, iontophoresis of I-CAP complex solution resulted in a flux of 9.29±1.19 µg/cm2 h which
is ~5 fold more compared to the passive permeation of I-CAP complex and control.

4. Conclusions
It was clear from the passive permeation studies that, the flux achieved from I-CAP complex was
almost equal to the flux achieved in case of control (50% alcohol). Since, alcohol is well
established as transdermal permeation enhancer, the flux achieved in case of passive delivery of
I-CAP complex can be considered as enhanced permeation. Further, the results from
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iontophoretic studies demonstrated the ability of CAP as permeation enhancer for lipophilic
drugs like ibuprofen.
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CHAPTER 5
TRANSDERMAL DELIVERY OF TESTOSTERONE (FROM CAP COMPLEX) FROM
A HYDROGEL FORMULATION

1. Introduction
Testosterone is the major circulating male androgen. Its deficiency is usually associated with
adverse effects on body composition, bone density, sexual function and mood, and may also
increase cardiovascular risk61. Gel formulations are already used clinically for the delivery of this
hormone (e.g. Androgel®). However, these formulations have to be applied over large surface
areas to achieve the target plasma levels which poses the risk of cross absorption who come in
contact with the treated individual. Therefore there is need for improving the rate of delivery of
testosterone from topical products to reduce the required area of application62.
The first major objective of this project was to explore if testosterone delivery across the skin
could be enhanced by iontophoresis, using CAP as complexing agent. The second objective was
to investigate the feasibility of complexation of CAP with lipophilic drugs from hydrogel
formulation (please note that the earlier investigations were performed in aqueous solution).

2. Materials
Sulphobutyl ether-β-cyclodextrin (Captisol®) was obtained as gift sample from Ligand
Pharmaceuticals, La Jolla, CA). Hydroxypropyl-β-cyclodextrin was obtained from Roquette
America, Inc (Geneva, IL). Testosterone was purchased from Sigma Aldrich (St. Louis, MO).
Ag wire was from Alfa Aesar, Ward Hill, MA. Dialysis membrane molecular weight cut off
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(MWCO) 1000Da was from Spectrum Chemicals, New Brunswick, NJ. All other chemicals used
were of research grade.

3. Methods
3.1.

Phase solubility studies

Phase solubility studies were performed according to the standard protocol. Solubility
measurements were carried out at constant temperature (25 ˚C) using different concentrations of
aqueous solution of CAP. A large excess of testosterone (200 mg) was added to 3ml of water
with accurately weighed amount of CAP and diluted to concentrations from 0.002 to 0.02 M in
screw capped scintillation vials. The resulted solution was vortexed for 5 min and was shaken for
5 days using rotary LabquakeTM tube shaker (Labindustries, Inc. Berkeley, CA). Then, an aliquot
of aqueous phase from each mixture was withdrawn, centrifuged for 15min at 13000 RPM and
the supernatant was collected and filtered through 0.45 µm cellulose acetate membrane filter. A
portion of clear filtrate was diluted appropriately and analyzed using high performance liquid
chromatography (HPLC).
3.2.

Preparation of solid complex mixture

Captisol-enabledTM testosterone (T-CAP) complex was prepared by freeze-drying method.
The aqueous solutions of complex were prepared by dissolving 100mg of drug in 10 mL of 10%
CAP in distilled water for testosterone, respectively. The resulting mixture was vortexed for
15min and sonicated for 20 min followed by setting aside at 25 ˚C for 48 h to attain equilibrium
solubility. The clear solution (10 mL) was then subjected to freeze drying for 24 h to obtain
white powder.
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3.3.

Transport studies across porcine epidermis from aqueous and hydro-

alcoholic solution
The vertical Franz diffusion apparatus (Logan Instruments, Somerset, NJ) was used for all
transport studies. The receiver compartment was filled with 5 mL of freshly prepared phosphate
buffered saline (PBS) (pH 7.4) with 30% alcohol and donor compartment with 0.5 mL of
permeant solution. In vitro passive permeation studies were carried out using aqueous solution
containing the drug-Captisol complex (dissolved in water) equivalent to 10 mg/mL of drug in the
donor compartment. As the pure drug is not soluble in water, a solution of pure drug dissolved in
50% alcohol was used as control at same concentration.
For in vitro iontophoretic permeation of complex, constant current cathodal iontophoresis
was applied using Phoresor® iontophoresis unit (Iomed, Salt Lake City, UT) at a current density
of 0.5 mA/cm2. Permeation studies were carried out from solution formulation after dissolving
the complex in water at same concentration as passive delivery (10 mg/mL) for a period of 24 h
and samples were analyzed using HPLC technique63.
3.4.

Preparation and release studies of testosterone from Hydroxypropyl Methyl

Cellulose (HPMC) Gels
HPMC gel was prepared by Hot/Cold technique at 3.5% w/v concentration. T-CAP complex
was incorporated at 10 mg/mL concentration in the gel. Further, the release of testosterone from
T-CAP gel formulation was investigated across 1000 Da molecular weight cutoff SpectraPor®
dialysis membrane using vertical Franz diffusion apparatus.
3.5.

Transport studies across porcine epidermis from HPMC gel formulation

Transport of testosterone from the HPMC gel formulation across porcine epidermis was
studied by both passive and iontophoretic mediated delivery for a period of 24 h and sample
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from the receiver compartment was withdrawn at pre-determined time points and estimated for
testosterone using HPLC63.

4. Results
4.1.

Phase solubility studies

The phase solubility studies revealed that different concentrations of aqueous solutions of
HPCD and CAP with testosterone in solution were correlated linearly representing an A L type
curve (Fig 12). From the phase solubility curves, the stability constant and complexation
efficiency of the two complex solutions was calculated and shown in Table 5.

Figure 12: Phase-solubility profiles of Testosterone in HP-β-CD and CAP.

HP-β-CD

SBE-β-CD

S0

5.18E-05

5.185E-05

m (Slope)

0.544

0.354

1-m

0.456

0.646
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S0 (1-m)

0.000

0.000

m/S0(1-m)

23008.9

10569.0

K 1:1

23008.9

10569.0

CE

1.193

0.548

Table 5: Summary of Cyclodextrin Stability Constants and Complexation Efficiency.
4.2.

NMR Studies

The formation of the complexes between testosterone and CAP was studied using 1H-NMR
spectroscopy. Proton NMR spectra were recorded from the solutions of CAP and T-CAP in D2O
to simulate the complexation in aqueous condition. The chemical shifts in case of protons
corresponding to CAP in the presence and absence of testosterone confirmed the formation of
inclusion complex64.
4.3.

Passive permeation studies

Passive delivery of T-CAP and T-HPC solution formulations resulted in 4.46±1.21 µg/cm2
and 7.74±3.71 µg/cm2 testosterone transported at the end of 24 h, which is comparable with the
cumulative amount of drug permeated in case of alcoholic solution of testosterone used as
control (5.11±0.68 µg/cm2) (Fig 13).
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Figure 13: Passive permeation profiles of T-CAP (■), T-HPC (♦) and testosterone dissolved
in 67% alcohol (▲) from solution formulations.
4.4.

Release studies of testosterone from HPMC gels

Release of testosterone from HPMC gel formulations with T-CAP and T-HPC complexes
was studied using 1000 Da molecular weight cut off membranes. The amount of drug released
was ~48% and ~44% at the end of 24 h with T-CAP and T-HPC complexes, respectively (Fig
14). The molecular weight of the T-CAP complex (2.3 kDa) and T-HPC (1.7 KDa) is way higher
than the MWCO of membrane (1 kDa), suggesting that the amount of drug in the receiver
compartment was predominantly due to the ability of CDs to enhance the thermodynamic
activity of drug in the donor compartment.
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Figure 14: Release profiles of testosterone from T-CAP (■) and T-HPC (♦) incorporated in
HPMC gel.
4.5.

Permeation studies across porcine epidermis from HPMC gel

The amount of testosterone permeated from these gel formulations across the porcine
epidermis in 24 h was found to be 2.45±0.92 µg/cm2 and 2.96±0.61 µg/cm2 with T-CAP and THPC, respectively (Fig 15). Decrease in the cumulative amount permeated across the porcine
epidermis compared to solution formulation can be accountable to increase in the viscosity due
to HPMC.
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Figure 15: Passive permeation profiles of T-CAP (■), T-HPC (♦) from gel formulations.
4.6.

Iontophoretic transport of T-CAP from solution and gel formulations

The cumulative amount of testosterone permeated after cathodal iontophoresis of T-CAP
complex solution was 124.85±8.01 µg/cm2, which is ~30-fold greater than passive delivery.
Further, iontophoresis using the hydrogel containing T-CAP resulted in permeation of
48.12±6.12 µg/cm2 (Fig 16). There was a significant change in the pH of the donor compartment
during iontophoresis was observed as the complex dissolved in water was used for iontophoretic
permeation studies instead of buffers to keep the solution devoid of any competing ions.
Considering the low pKa value of sulfonic acid groups on the CAP, an increase in the pH in
donor compartment due to hydrolysis of water during iontophoresis is not likely to affect the
iontophoretic transport significantly65. To minimize the effect of pH changes on the permeation
of drug across the skin, the drug solution in the donor was replaced intermittently with freshly
prepared drug-CAP complex solution.

46

Figure 16: Passive permeation profiles of T-CAP from solution (●) and HPMC gel (▲)
formulations and Iontophoretic permeation profiles of T-CAP from solution (■) and
HPMC gel (♦) formulations.
5. Conclusions
The results from these studies demonstrate that the cyclodextrin derivatives CAP and
HPβCD could be used to deliver lipophilic molecules like testosterone from semisolid
preparations. The use of these cyclodextrin derivatives could potentially eliminate the use of
alcohol in the formulation. Further, iontophoresis of T-CAP complex solution resulted in a flux,
which is ~25 fold more compared to the flux achieved in case of control (Testosterone dissolved
in 67% alcohol) and ~48 fold more when compared to passive delivery of T-CAP complex.
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CHAPTER 6
MECHANISMS CONTRIBUTING TO TRANSDERMAL TRANSPORT OF
LIPOPHILIC DRUGS COMPLEXED WITH CAPTISOL

1. Introduction
Propofol:captisol® (P-CAP) complex was used to investigate the potential mechanisms
responsible for enhancement of transdermal delivery of drug when complexed with CAP. From
passive permeation standpoint, stratum corneum has been known to be permeable to small (<500
Da) and moderately lipophilic molecules only66. The P-CAP complex is about 2 kDa, which is
way above the known size-exclusion limit of stratum corneum. However, there was a significant
enhancement in the delivery of propofol from P-CAP complex. Initially, it was not clear if the
whole intact complex would be able to transport across the epidermis or its propagation is
limited only up to the donor-epidermal interface. The other question that arises was if at all the
transport of intact complex across the epidermis is practical, then would application of
iontophoresis drive more intact complex due to electrorepulsion? This is because; the
electrorepulsion is known to diminish as the size of the molecule increases67. Electrorepulsion is
determined by charge to mass ratio, rather than the charge alone. To address these questions,
transport studies were performed to investigate the permeation of neat CAP across the porcine
epidermis. Also, the effect of CAP on the structural integrity of stratum corneum was studied
using FTIR and skin electrical resistance studies. Further, to demonstrate the effect of CAP in
enhancing the thermodynamic activity in the donor compartment, transport studies were
performed across a non-biological membrane.
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2. Materials
Sulphobutyl ether-β-cyclodextrin (Captisol®) was obtained as gift sample from Ligand
Pharmaceuticals, La Jolla, CA). Ibuprofen, testosterone and propofol were purchased from
Sigma Aldrich (St. Louis, MO). Ag wire was from Alfa Aesar, Ward Hill, MA. Dialysis
membrane molecular weight cut off (MWCO) 1000Da was from Spectrum Chemicals, New
Brunswick, NJ. All other chemicals used were of research grade.

3. Methods
3.1.

General in vitro experimental setup

A vertical Franz diffusion apparatus (Logan Instruments, Somerset, NJ) was used for all
resistance, transport and mechanistic studies. A piece of epidermis was placed between the donor
and receiver compartments with temperature maintained at 37±1 ˚C using water circulator.
Effective surface area for transport studies was kept constant at 0.64 cm2. The receiver
compartment was filled with 5 mL of freshly prepared phosphate buffered saline (PBS) (pH 7.4)
with 30% methanol and donor compartment with 0.5 mL of permeant solution. The electrical
resistance of epidermis was measured with the help of an electric circuit consisting of a
waveform generator and digital multimeter (Agilent Technologies, Santa Clara, CA). Epidermis
with a resistance ≥20 kΩcm2 was considered for permeation studies. One mL of sample from the
receiver compartment was withdrawn at pre-determined time points and estimated for propofol
using HPLC.
3.2.

Trans-epidermal transport of Rhodamine labeled Captisol®

In vitro iontophoretic and passive transport of Rhodamine labeled CAP (R-CAP) was carried
out across the porcine epidermis. 0.5 mL of 18% w/v of R-CAP was placed in the donor
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compartment. The experimental setup remains same as described in previous section. Samples
from the receiver compartment was collected and for the amount of R-CAP was measured using
fluorescent spectroscopy at excitation wavelength of 515 nm and emission wavelength of 556
nm. The R-CAP concentration was calculated from the standard calibration curve made by using
different standard concentrations of R-CAP68.
3.3.

Trans-epidermal electrical resistance studies

Freshly excised porcine epidermis having a resistance of ≥20 kΩcm2 was chosen for carrying
out the studies. The electrical resistance of skin was measured with the help of an electric circuit
consisting of a waveform generator and digital multimeter having a load resistor RL (100 kΩ) in
series with the skin. Ag/AgCl electrode wires of 0.5 mm diameter (Alfa Aesar, Ward Hill, MA)
made in the form of concentric rings were placed 2 mm away from the porcine epidermis in both
the donor and the receiver compartments to measure the electrical resistance. The voltage drop
across the whole circuit (V0) and across the skin (Vs) was measured and skin resistance was
determined by applying a voltage of 100 mV at 10 Hz in the circuit. The drop and recovery of
electrical resistance in presence of CAP in the donor compartment during and after iontophoresis
were recorded. PBS in the donor compartment was used as test solution in control experiments.
3.4.

FTIR spectroscopy

Porcine epidermis was separated from the dermis of full thickness skin by heat stripping
technique. Isolated epidermis was then floated over 0.25% w/v trypsin solution overnight at
room temperature to digest the epidermis69. The residual stratum corneum (SC) was then washed
with phosphate buffer and dried at room temperature for 48h. The SC was then cut into square
pieces of 2 X 2 cm. Each piece was placed in the 10% w/v and 20% w/v of CAP solution in
water, whereas SC placed in the buffer was used as control. SC pieces were incubated in
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solutions for a period of 24 h and then washed thoroughly with water to remove any excess CAP
on surface. The SC pieces were then dried at room temperature for 48 h at the end of which
interferograms were recorded. Mid-infrared spectra were collected on an FTIR (Agilent
Technologies Cary 660). The bench was equipped with a sampling accessory (MIRacle ATR,
Pike Technologies), which was fitted with a single bounce diamond coated ZnSe internal
reflection element. The spectra were collected from 4000-650cm-1. The spectra were analyzed
using the Agilent’s software suite (Resolutions Pro Version 5.2.0). Each sample was studied in
triplicate to assess its effect on the SC.
3.5.

Transport studies across dialysis membrane

Passive and iontophoretic transport studies of propofol and P-CAP complex solutions at 10
mg/mL concentration was carried out using dialysis membrane (1000 Da MWCO). The
experimental setup remained similar to general experimental setup, except that the porcine
epidermis was replaced with dialysis membrane. Iontophoresis of P-CAP complex was carried
out at a current density of 0.5m A/cm2.
3.6.

Effect of pretreatment with chemical permeation enhancers

Different CPEs include, 5% w/v menthol, propylene glycol (PG), oleic acid (OA), and
ethanol was used to investigate the effect on iontophoretic delivery of propofol from P-CAP
complex with the experimental setup remain same as described in section 2.1. Initially, porcine
epidermis was treated with CPEs for a period of 3 h and followed by washing thoroughly with
distilled water. Then the donor compartment was filled with 0.5 mL of P-CAP solution and
iontophoresis was performed at a current density of 0.5 mA/cm2.
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3.7.

MTT assay

Cell viability of dermal fibroblast derived from humans (CCD-1093Sk) was studied using the
CAP solutions. Fibroblast cultures were stored and handled according to the standard protocol
from ATCC. To study the effect of the CAP formulation on cell viability, cell cultures were
exposed to different concentrations ranging from 0.5 to 2 % w/v for a period of 24 h. Each test
formulation

was

studied

in

eight

trials.

MTT

carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)

(3-(4,5-dimethylthiazol-2-yl)-5-(3cell

proliferation

assay

was

performed according to the protocol supplied by Promega. The optical absorbance data from the
samples were then used to calculate the percentage cell viability.

4. Results and Discussion
4.1.

Transport of Rhodamine labeled Captisol® across the porcine epidermis

Some earlier works have already reported that skin permeable to different cyclodextrins to
different extents in the molecular weight range of ~1kDa72-75. Gerloczy and co-workers reported
that [14C] Dimethyl-β-Cyclodextrin was poorly absorbed (0.3-0.4%) when the ointment at 40 49 mg/mL concentration was applied onto the skin of rats under occlusive conditions75. In
another study, Tanaka and co-workers have reported that, 0.02% of HPCD was absorbed into
hairless mouse skin under occlusive conditions at 20 mg/mL concentration in the donor
compartment74. There is no data available regarding the passive and iontophoretic transdermal
transport of CAP. Due to lack of sensitive methods of measurement of cyclodextrins, rhodamine
labeled CAP (R-CAP) was used to investigate the permeability of CAP across the epidermis. The
in vitro passive and iontophoretic permeation of R-CAP was studied to approximate the amount
of propofol permeated in the form of intact complex. The amount of R-CAP permeated passively
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was 0.16% (150.24±48.31 µg/cm2 in 8 h). Although relatively small amount, the fact that CAP
permeated across the epidermis itself was interesting. This data suggests that despite the huge
molecular size, the possibility of transport of intact P-CAP complex cannot be completely ruled
out. Iontophoresis enhanced the transport of R-CAP to ~0.87% (804.43 ± 94.12 µg/cm2 in 8 h), a
fivefold enhancement suggesting significant elelctrophoretic driving of the molecule. The
efficiency of electrophoresis of R-CAP across the epidermis is likely because of the seven
negative charges present on the molecule, which makes up for its huge molecular size with a
transport number 0.003. The transport number of unit charge carrying smaller molecules which
were successfully delivered transdermally by iontophoresis, such as diclofenac sodium is about
0.00376, 77. This explains how R-CAP could appreciate the electrorepulsion mediated transport
across the epidermis despite its relatively larger molecular size.
To approximate the extent of transport of intact complex across the epidermis, one needs to
look at the cumulative amount of propofol transported versus the total cyclodextrin transported
across the epidermis. The cumulative amount of the propofol transported across the porcine
epidermis from the P-CAP complex at the end of 8h was ~0.6 X 10-3 mmol and ~0.24 X 10-2
mmol by passive and iontophoresis, respectively. If all of propofol had transported in the form of
intact complex, the amount of CAP transported should be equivalent to the amount of propofol.
However, in reality, the cumulative amount of propofol permeated was found to be more when
compared to the cumulative amount of CAP permeated at the end of 8h (~ 0.69 X 10-4 mmol
passively and ~0.37 X 10-3 mmol by iontophoresis). This data suggests that the transport of
propofol cannot be absolutely in the intact P-CAP complex form. There appears to be
contribution by other mechanisms as well.
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4.2.

Resistance studies of porcine epidermis

To investigate the effect of CAP on the stratum corneum barrier, electrical resistance drop
and recovery studies were carried in the presence of CAP at 18% concentration (concentration at
which CAP is complexed with propofol for transport studies across the porcine epidermis). For
control studies, electrical resistance of the epidermis was studied in the presence of freshly
prepared PBS. Yamamoto and Yamamoto have demonstrated that the skin’s electrical resistance
resides primarily in the SC78. Skin resistance decreased as layers of the SC were removed by tape
stripping. They also reported that the passage of ions into and across the skin was increased, if
the barrier function of SC is reduced in some way. Rachakonda and co-workers have studied
extensively on skin electrical resistance after treating with chemical permeation enhancers. From
the results, they found that electrical resistance measurement could be used to determine the
effect of CPEs on the barrier property of skin79.
In case of iontophoresis, the major route of ionic transport has been found to be appendageal
pores including sweat ducts and hair follicles80. Apart from appendageal pathway, there are
reports on formation of artificial shunts as a result of temporary disruption of organized structure
of SC upon application of iontophoresis81. Caullander also reported the pore formation is
dependent on the current potential applied and this can attribute to the flip-flop movements in
polypeptide helices82.
In the present study, the effect of CAP on the recovery of skin barrier perturbed due to
iontophoresis treatment was investigated. The drop and recovery in the porcine epidermal
resistance following iontophoresis at a current density of 0.5 mA/cm2 was studied with PBS and
CAP solutions in the donor compartment. Drop in the electrical resistance was recorded using
digital multimeter and waveform generator for a period of 1 h at every 5min interval.
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Iontophoresis was stopped after 1 h and the recovery in the electrical resistance of the epidermis
was recorded while retaining the donor solution. From the graph (Fig 17) plotted between
relative resistance vs time, it clearly shows the delay in the recovery process in case of donor
with CAP, whereas with PBS, there was a recovery up to ~90% within 2 h. The prolonged
contact between CAP and epidermis did not lead to any significant drop/change in the electrical
resistance compared to PBS in the absence iontophoresis (which served as control in this set of
experiments).
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Figure 17: The epidermal resistance as an indicator of permeability status of the porcine
epidermis
Sen and co-workers have studied the effect of anionic phospholipids on transdermal
permeation after electroporation. They found that, only anionic lipids are expected to disrupt the
tightly packed SC lipid lamellae and prolong the opening of the pathways83. In another study,
Stewart and co-workers found that anionic lipids prefer loosely packed multi lamellae and are
prone to develop and retain vesicular form upon physical perturbation, such as electric pulses,
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thereby prolong the recovery84. CAP being a multi-anionic substance, it is likely to prolong the
permeability status of the epidermis perturbed due to iontophoresis by a mechanism somewhat
analogous to the anionic lipids reported earlier. It is intriguing to observe that the barrier
recovered by 70% within two hours after replacing the donor compartment with PBS.
4.3.

FTIR spectroscopy of SC

There was no significant shift in the peaks in the lipid region (2920 and 2850 cm−1) or in the
amide regions (1650 and 1550 cm−1) as clearly seen in the representative spectra shown in Fig.
18, even after exposure to 20% w/v CAP solution for a period of 24 h. This data supplements the
hypothesis that the CAP used in this project has negligible or no effect on the skin structure69.
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Figure 18: Representative FT-IR spectra of stratum corneum (Control and 20% CAP
treated) and CAP.
4.4.

Transport studies across dialysis membrane

Generally, CDs are known to act as carriers for the drug molecules and increases the
availability of drugs at the membrane-reservoir interface. This in turn increases the concentration
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gradient of drug across the membrane, resulting in enhanced driving force for permeation 85, 86.
To investigate if this is one of the potential mechanisms of permeation enhancement in case of
propofol, the permeation studies were performed across a non-biological membrane (to avoid
any interference due to biological factors), dialysis membrane of 1000 Da cut off molecular size.
The permeation flux resulted from the passive transport studies of propofol and P-CAP was
found to be 31.88±11.61 µg/cm2/h and 59.75±8.74 µg/cm2/h, respectively (Fig 19). The
molecular weight of the complex (2.3 kDa) is way higher than the MWCO of membrane (1 kDa),
suggesting that the enhanced transport (~2 fold) in passive permeation across the dialysis
membrane was predominantly due to the ability of CAP to enhance the thermodynamic activity
of drug in the donor compartment as observed in case of other CDs73, 86, 88.

Figure 19: Passive permeation studies across dialysis membrane (1 kDa). Donor
compartment was placed with propofol (▲), P-CAP complex (equivalent to 10 mg/ml
propofol) (■) and iontophoretic transport of propofol from P-CAP complex (♦).
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Electrophoresis and electro-osmosis are the two major mechanisms involved in driving of
ions upon application of current across the membranes89. Since the isoelectric point of skin is
between 4 – 4.5 and is negatively charged under physiological conditions; electro-osmosis
occurs only in anode to cathode direction, whereas in case of cathodal iontophoresis
electrorepulsion is the only mechanism driving the drug predominantly. Cathodal iontophoresis
of P-CAP complex at the current density of 0.5 mA/cm2 lead to a transport flux of 134.83 ± 9.15
µg/cm2/h of propofol (Fig 3), which is ~4.5 fold higher than passive permeation of propofol
when neat propofol was placed in the donor and ~2.2 fold higher when compared to passive
permeation from P-CAP complex. Again, as the transport of intact complex is not possible across
the membrane used in this study, it is likely that the applied electric current drove the charged
complex only up to the membrane surface. This essentially would enhance the transport of drug
across the membrane.
From the studies performed so far, it was evident that the passive permeation of drug was
enhanced due to the mechanisms such as permeation of intact complex as well as due to the
property of CAP to enhance the availability of drug at the membrane surface. In case of
iontophoresis, the enhanced trans-epidermal drug transport was due to electrophoresis of intact
complex leading to enhanced transport of intact complex as well as profoundly increased
availability of drug at the membrane surface. However, the results discussed so far, did not
reveal any information regarding the potential effects of CAP on the stratum corneum barrier.
Therefore, further sets of studies were performed to investigate the effect of CAP on the stratum
corneum barrier upon iontophoresis in the presence of CAP in donor compartment.
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4.5.

Effect of pre-treatment with chemical permeation enhancers

The effect of pretreatment with CPEs on the iontophoretic transport of propofol from CAP
complex was investigated to assess if the combination approach could be utilized to achieve
higher doses of drugs if required. CPEs are known to decrease the skin’s barrier integrity of
stratum corneum. However, due to the heterogeneity of skin structure, there exists number of
different mechanisms by which these CPEs shows their action90. Kalia and Guy have studied the
effect of pre-treatment with CPEs on iontophoresis across human skin using skin resistance as a
tool91. From the studies they reported that, pre-treating with CPEs reduced the skin resistance
and further decrease in the skin resistance was observed upon iontophoresis at current density of
0.2 mA/cm2.

Figure 20: In vitro iontophoretic transport of propofol from P-CAP complex after
pretreatment with different chemical permeation enhancers for 3h. Transport profile of
propofol after pre-treating with 100% v/v Ethanol (X), 100% v/v Propylene Glycol (■), 5%
w/v Menthol in 50% v/v Ethanol (●), 100% v/v Oleic Acid (♦) and PBS (control) (▲).
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In the present study, the flux resulted from the in vitro iontophoretic transport of P-CAP
complex after pre-treating with 100% v/v PG and 100 % v/v OA was found to be 47.96±4.54
µg/cm2/h and 20.74±0.48 µg/cm2/h, which was less compared to control (62.35±5.27 µg/cm2/h).
PG was chosen as enhancer, since it was reported to enhance the permeability of propofol across
rat skin90. Despite the enhanced permeability of propofol when PG was used in the formulation,
pre-treatment did not enhance the iontophoretic transport of propofol from P-CAP complex. It
has been reported that, oleic acid facilitates transport through intercellular lipid domains by
forming OA pool in the stratum corneum91. The iontophoretic transport of hydrophilic P-CAP
complex might have reduced the flux when epidermis was pretreated with oleic acid. Menthol
was another permeation enhancer evaluated in the study. Pre-treatment with 5% w/v of menthol
in 50% w/w alcohol did not enhanced the flux (56.89±2.41 µg/cm2/h) when compared to control.
This data also show that ethanol at 50% v/v lacks the ability to enhance the transport of propofol
from P-CAP complex. Whereas, Pre-treatment with 100% v/v ethanol was found to enhance the
flux by ~two fold (116.52±10.47 µg/cm2/h) (Fig 20). Ethanol mainly acts as permeation
enhancer by increasing the partitioning in to stratum corneum92. Overall this study showed that
the iontophoretic transport of propofol from P-CAP complex could be further enhanced when
appropriate enhancer is used.
4.6.

MTT assay

The MTT assay is a tool to assess the safety of captisol for dermal use. The previous studies
have shown that CAP appears to penetrate the skin in significant amounts69. Thus, cell viability
studies on fibroblast (derived from humans) were performed at different concentrations of CAP
solutions. The cell viability of non-treated cells was considered as 100%. More than 80% of cells
were viable at 1.5% w/v concentration of CAP (Fig 21), with further increase in concentration to
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2% w/v the % cell viability decreased to 76%, which is likely due to increased osmotic pressure
in the medium (2% captisol in culture media has an osmotic pressure of 426 mOsmo/L).

Figure 21: MTT assay of CAP at different concentrations.

5. Conclusions
Mechanistic studies reveled the fact that CAP can permeate the epidermis and its transport
could be enhanced significantly by iontophoresis. The results from the in vitro permeation
studies showed that the passive permeation of propofol could be enhanced by complexing with
CAP. The predominant mechanisms responsible to enhanced drug permeation are transport of
intact complex and increased localization of drug at the surface of the membrane. The
mechanisms contributing to enhanced delivery of propofol from P-CAP complex by
iontophoresis additionally includes electrorepulsive transport in the form of intact complex,
profoundly increased localization of drug at the membrane surface and prolonged recovery phase
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of skin barrier compromised due to iontophoresis. Further, the results from the MTT assay
indicate the biocompatibility of CAP.
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